Asertin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asertin

Property Description
Active ingredient Sertraline Hydrochloride
Form Oral Film-Coated Tablet
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Mood and Emotional Stabilization
Origin Synthetic Compound

Defining the Drug Entity and Its Classification

Asertin is the trade name for a synthetic, single-ingredient medication containing the active substance Sertraline Hydrochloride. This compound is a Selective Serotonin Reuptake Inhibitor (SSRI) (ATC code N06AB06), positioning Asertin as a core agent within the broader group of psychotropic agents designed to influence the central nervous system. This classification describes its targeted action within the context of modern antidepressant therapies. Sertraline acts as a centrally acting agent, designed to work directly on the brain's chemical pathways.


Composition, Origin, and Pharmaceutical Form

The pharmaceutical preparation is supplied for oral administration most commonly as a film-coated tablet. Asertin is a single-ingredient product, where the therapeutic effect is attributed to the Sertraline Hydrochloride molecule. The use of the hydrochloride salt ensures chemical stability and consistent delivery of the active substance. Sertraline is an oral preparation intended for the long-term management of emotional distress and mood disorders. As a synthetic derivative, Sertraline is manufactured chemically, ensuring consistency in the quality and concentration of the active ingredient.


General Therapeutic Purpose of Selective Serotonin Modulation

For instance, it is typically used in a scenario where a patient requires support in managing persistently low mood or excessive worry. The general purpose of this medication is to help restore and maintain chemical balance in the brain. Its role as an SSRI means its action is linked to enhancing the availability of the neurotransmitter serotonin in the synaptic space. This selective serotonin modulation provides the biochemical foundation for stabilizing emotional responses and improving mood. By regulating these critical brain pathways, Asertin serves as a mechanism to support overall psychological well-being.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Asertin?

Possible Side Effects and Safety Information

The safety profile for Asertin (Sertraline Hydrochloride) is classified by regulatory authorities based on frequency and affected physiological system. Adverse reactions commonly involve the gastrointestinal and nervous systems.


Frequency and Organ System Classification

Classification Examples of Documented Effects
Very Common (ge 1/10) Nausea, Diarrhea, Dry Mouth, Insomnia, Fatigue
Common (ge 1/100 to <1/10) Dizziness, Somnolence, Tremor, Decreased Appetite, Sexual Dysfunction (e.g., Ejaculation Failure)

Serious Safety Concerns

Regulatory warnings highlight the potential for certain rare but serious adverse reactions. These include Serotonin Syndrome, especially when the medication is combined with other serotonergic agents. There is also an official warning concerning the increased risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults during the initial months of treatment or following dose adjustments.

Other serious risks documented in the label are the potential for Activation of Mania or Hypomania, Hyponatremia (low sodium levels), and an Increased Risk of Bleeding.


Population and Time-Related Safety

Specific safety considerations apply to certain groups. Older adults may be at a greater risk for Hyponatremia. Caution is formally advised for patients with hepatic impairment due to reduced clearance, which increases the body's exposure to the medication. The risk of Discontinuation Syndrome, which includes symptoms like dizziness and sensory disturbances, may occur upon abrupt cessation of treatment. Use is also formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Asertin (Sertraline) may result in symptoms of serotonin-mediated toxicity. The official regulatory classification of overdose manifestations includes central nervous system effects such as somnolence, tremor, agitation, confusion, and dizziness. Gastrointestinal disturbances, including nausea and vomiting, and cardiovascular effects, such as tachycardia (fast heartbeat), are also documented presentations. Less frequent, but officially reported, severe outcomes include seizures and coma (loss of consciousness).

Severe Manifestations and Required Action

Any suspected overdosage must be treated aggressively and requires immediate medical attention. A critical, life-threatening risk reported in regulatory documents is Serotonin Syndrome, which is characterized by symptoms like severe muscle stiffness, hyperthermia (fever), and rapid heart rate. Overdosage may also involve QTc prolongation, which requires cardiac monitoring.

When to Contact Emergency Services

Call the Poison Control helpline immediately upon recognizing any sign of overdose. If the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediately call emergency services (911/equivalent).

Management and Antidote Status

There is no specific antidote known for Sertraline overdosage. Management is symptomatic and supportive. Regulatory documents recommend continuous ECG (cardiac) and vital sign monitoring. Activated charcoal may be considered for recent ingestions. Fatalities most frequently occur when Sertraline is ingested in combination with other drugs or alcohol.

Therapeutic Uses of Asertin

What Asertin Treats: Main Uses and Benefits

Asertin, containing sertraline, is commonly used across conditions presenting with episodic or fluctuating mood and anxiety patterns. These include Major Depressive Disorder (MDD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). Its application is intended to support symptomatic relief across mood and anxiety domains.

The medication is applied in addressing symptom clusters that create noticeable functional strain, particularly persistent sadness, unwanted intrusive thoughts, and intense fear or panic. It is relevant when supportive symptom management is appropriate, and may assist with managing symptoms associated with acute or episodic changes.

“The support provided contributes to improved comfort during symptomatic periods and assists with maintaining functional stability.”

Quick Fact: Relief for Intense Anxiety Asertin supports patients during difficult episodes by easing the psychological and physical manifestations of acute fear and worry associated with Panic Disorder and PTSD.

Regulatory References

  1. NIH MedlinePlus overview of Sertraline

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Asertin (Sertraline)

Official regulatory documents define strict population eligibility criteria for Asertin, which contains sertraline. Use is based on age, specific medical conditions, and concurrent treatments.


Absolute Contraindications

Use is strictly prohibited in patients with a known hypersensitivity to sertraline and those receiving Monoamine Oxidase Inhibitors (MAOIs) or Pimozide.


Age- and Condition-Specific Eligibility

Age Group Eligibility Status
Adults (18+ years) Approved for all labeled indications.
Children/Adolescents (6–17) Approved for Obsessive-Compulsive Disorder (OCD) only; use for other conditions is not established.
Children Under 6 years Use not recommended or established for any indication.

Organ Function and Condition-Based Restrictions

Use is not recommended for individuals with severe hepatic impairment or unstable epilepsy. Patients with mild to moderate hepatic impairment require a lower or less frequent dose. While use is permitted in renal impairment, caution is advised for older adults and those with risk factors for QTc prolongation.


Maternal Status

Use during pregnancy should generally be avoided unless the benefit outweighs the potential risk. Sertraline is excreted in breast milk, and use during lactation requires careful risk-benefit assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Asertin (sertraline) carries a risk of interaction with several classes of medications and products, primarily due to its effect on serotonin levels and its involvement in drug metabolism.

Contraindicated Combinations

The use of Asertin is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including the MAOIs linezolid and intravenous methylene blue. This combination may lead to the development of Serotonin Syndrome, a potentially severe condition. A washout period of at least 14 days is required when switching between Asertin and an MAOI. Additionally, concomitant use with pimozide is contraindicated due to an increase in its concentration.

Clinically Significant Interactions

  • Serotonergic Agents: Co-administration with other serotonergic medicines (e.g., triptans, tramadol, fentanyl, St. John's Wort) increases the risk of Serotonin Syndrome and requires careful monitoring.
  • Antiplatelet Agents and Anticoagulants: Concomitant use with aspirin, NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), or warfarin may increase the risk of bleeding events, as sertraline can impair platelet aggregation.
  • CYP2D6 Substrates: Sertraline acts as a weak inhibitor of the CYP2D6 enzyme. This may lead to increased exposure and toxicity of medications primarily metabolized by this enzyme.
  • Oral Solution: The oral solution contains alcohol and is contraindicated with disulfiram to avoid a disulfiram-alcohol reaction.

Mechanism of Action

Asertin (sertraline) primarily acts within the central nervous system as a selective serotonin reuptake inhibitor (SSRI). Its principal molecular target is the Serotonin Transporter (SERT), a presynaptic transmembrane protein responsible for recapturing serotonin (5- HT) from the synaptic cleft into the presynaptic neuron.

Asertin functions as an inhibitor, binding non-covalently to SERT and blocking the reuptake mechanism. This blockade leads to an immediate increase in the concentration of free serotonin in the synaptic cleft, thereby enhancing serotonergic neurotransmission. With chronic administration, the persistent elevation of synaptic serotonin is hypothesized to induce downstream desensitization and downregulation of certain presynaptic 5- HT1A autoreceptors. This process facilitates a long-term increase in the firing rate of serotonergic neurons, further augmenting 5- HT release and contributing to system-level modulation of monoamine pathways, including indirect effects on norepinephrine and dopamine signaling.

Dosage and Administration Information

How to Use Asertin (Sertraline)

The following details the standard administration guidelines for this medication.

Administration Scope Guideline
Route Oral (by mouth).
Tablets May be taken with or without food.
Capsules Must be swallowed whole; do not crush or chew.
Frequency Once daily (Q.D.) in the morning or evening.

Official Dosing and Titration Rules

The maximum dosage for most conditions is 200 mg per day. The initial dosage and maximum dosage are subject to the specific condition being addressed.

Population/Condition Initial Dose Titration Rule
Adults (MDD, OCD) 50 mg/day Adjustments of 25 mg to 50 mg are made at intervals of at least one week.
Adults (PD, PTSD, SAD) 25 mg/day Increase to 50 mg/day after one week. Further adjustments are made weekly.
Pediatric (OCD) 25 mg/day (6-12 yrs) or 50 mg/day (13-17 yrs) Increases of 50 mg are made weekly up to 200 mg/day.

Preparation Requirements for Oral Solution (20 mg/mL)

For the oral solution, the measured dose must be diluted immediately before use. Measure the dose using the supplied calibrated dropper. Mix the solution with 4 ounces (1/2 cup) of water, ginger ale, lemon/lime soda, lemonade, or orange juice ONLY. The mixture must be drunk immediately.

Special Procedural Notes

The dosage should be reduced gradually when discontinuing the medicine to avoid potential symptoms. For patients with mild hepatic impairment, the recommended starting and maximum dosages should be halved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asertin (Sertraline)

Evidence for Use in Major Depressive Disorder (MDD)

The research for Major Depressive Disorder (MDD) has primarily relied on Randomized Controlled Trials (RCTs). These short-term studies, typically lasting 6 to 12 weeks, were used in research exploring how symptoms change over time. Researchers examined changes measured using standardized rating scales for depressive symptoms. In longer-term research, randomized withdrawal trials were applied in studies examining patient-reported experiences related to the prevention of symptom recurrence. These maintenance studies monitored subjects who had already achieved a measured level of stability.

What remains uncertain is the full breadth of findings, as some systematic reviews noted high statistical variability across different clinical trials evaluated. Furthermore, the long-term recurrence prevention data often applies only to the populations studied—specifically subjects who already achieved a measured level of stability—meaning research provides limited insight into the general population.


Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research for Obsessive-Compulsive Disorder (OCD) was evaluated in placebo-controlled RCTs, typically lasting 10 to 16 weeks for the acute phase. Studies explored outcomes related to physical discomfort and daily functioning. Researchers primarily used the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) to measure changes in symptom intensity.

Studies conducted during periods of increased symptom activity described patterns where a measured change in symptom severity was evident across studies involving both adult and children and adolescents. A key research limitation is that data for certain groups remain insufficient; the available evidence provides limited information regarding long-term measurements in children and adolescents.


Evidence for Use in Panic Disorder (PD) and Anxiety Syndromes

The research base for conditions involving periods of heightened symptoms, such as Panic Disorder (PD), primarily consists of short-term, placebo-controlled clinical trials. Studies monitored outcomes such as the frequency of panic attacks. Evidence also suggests measured change was observed in some studies that examined related syndromes, including Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD). Research examined PTSD in short-term RCTs, monitoring changes using standardized PTSD symptom severity scales.

Evidence is limited for long-term outcomes related to the stability of measured change in panic attack frequency, as there is limited controlled information for outcomes extending beyond the initial 12 weeks. Similarly, long-term effects for PTSD are not fully established, as follow-up durations were often limited to the acute observation period.


Understanding the Evidence Gaps and Areas of Uncertainty

Research highlights what is known—and what is still uncertain—about Asertin. A key research limitation is that comparative evidence is lacking for many specific outcomes against other active treatments. Furthermore, the evidence quality varies across studies, and some meta-analyses show notable variability in findings. Limited information for long-term outcomes is a common gap across several indications. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration (Major Depressive Disorder)
  2. Sertraline increased the response rate and improved symptoms in post-traumatic stress disorder: a randomized controlled trial

Frequently Asked Questions (FAQ)

Common questions about Asertin (FAQ)

Q: What is Asertin used for in simple terms?

A: This medication is used to help manage symptoms of Major Depressive Disorder (MDD). It is also officially indicated for several anxiety-related conditions, including Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), and Social Anxiety Disorder (SAD).


Q: Is Asertin known by other brand names?

A: Yes, Asertin is a brand name for the active ingredient Sertraline Hydrochloride. This active substance is also marketed globally under various other brand names, such as Zoloft, meaning they contain the exact same active medicinal substance.


Q: How quickly do people usually start to feel a change with Asertin?

A: Studies indicate that the full therapeutic effects are typically delayed, often taking between two to four weeks to become evident. Some patients may report experiencing changes in energy or alertness earlier in the treatment course.


Q: How long does Asertin stay in your system after stopping it?

A: Official pharmacokinetic data shows that the active ingredient, sertraline, has an elimination half-life ranging from 22 to 36 hours. Its main active component has an even longer half-life, ranging from 56 to 120 hours.


Q: Does Asertin cause weight gain?

A: The official list of adverse reactions includes both weight loss and weight gain among the reported side effects. Decreased appetite is also specifically listed as a common effect of the medication.


Q: Is feeling more anxious at the start a common side effect of Asertin?

A: Regulatory information advises monitoring patients for the emergence of symptoms such as new or worsening anxiety, agitation, and panic attacks. This is especially important during the initial period of treatment or when the dosage is changed.


Q: Is it safe to drink alcohol while taking Asertin?

A: Official regulatory information advises that this medication should not be used with alcohol. Alcohol may intensify certain side effects of the medication, such as dizziness or drowsiness.


Q: What happens if I miss a dose of Asertin?

A: According to official patient information, if a dose is missed, patients are advised not to take a double dose. They should simply take the next scheduled dose at the regular time.


Q: How long does a person typically need to take Asertin?

A: The required duration of treatment varies widely and depends on the condition being treated and the patient's response. Clinical trials include data on maintenance therapy for Major Depressive Disorder, which is used for the prevention of symptoms returning.


Q: Is there a risk of dependence or addiction with Asertin?

A: Official studies indicate that this medication has not demonstrated potential for abuse or addiction in humans. However, abruptly stopping the medication can lead to symptoms of Discontinuation Syndrome.


Q: Is Asertin known to affect blood pressure?

A: As an SSRI, this class of drugs is generally characterized by a limited impact on blood pressure compared to other drug types. However, an abrupt increase in blood pressure can be a serious symptom of Serotonin Syndrome, a warning condition associated with this medicine.


Q: What should I do if the side effects of Asertin are bothersome?

A: If side effects become bothersome or persistent, regulatory instructions and patient leaflets advise patients to consult a healthcare professional for guidance.


Q: Is Asertin the same as Zoloft?

A: Asertin is a brand name for the active ingredient Sertraline Hydrochloride. The medication is also marketed under the brand name Zoloft, meaning they contain the exact same active medicinal substance.


Q: Does Asertin cause any issues with driving or operating machinery?

A: Regulatory documents explicitly state that psychotropic drugs, including this medication, may influence the ability to drive or use machines. The advice for patients is not to drive or operate machinery until they are aware of the medication’s specific effects.


Q: Is it normal to feel a bit restless after starting Asertin?

A: Regulatory information advises monitoring for the emergence of symptoms such as agitation or restlessness, especially early in treatment or following dose adjustments. Patients are generally advised to discuss these feelings with a medical professional if they become a concern.


Q: Does Asertin interact with birth control pills?

A: Official drug interaction data suggests that no significant interaction is expected between this medication and oral contraceptive pills. Therefore, no additional dose adjustments or precautions are typically needed regarding the pill's effectiveness.


Q: How do I know if Asertin is starting to work?

A: The medication's effects are generally measured by a noticeable reduction in symptoms related to the condition being treated. This usually includes a decrease in the severity of depressive symptoms, the frequency of panic attacks, or the intensity of compulsions, often occurring after several weeks.


Q: Can Asertin cause sweating or temperature changes?

A: Yes, regulatory documents list excessive sweating (hyperhidrosis) as a documented side effect of the medication.


Q: Can Asertin make me feel emotionally numb?

A: Official data addresses adverse events that can affect emotional state. Some patients report changes, such as apathy or a diminished emotional response, which may be related to the medication’s effect on brain chemistry.


Q: What is the difference between a side effect and an allergic reaction to Asertin?

A: A side effect is a generally predictable, adverse reaction (e.g., nausea) listed in the product information. An allergic reaction is a rare and potentially serious immune response, often indicated by symptoms such as hives or swelling, and constitutes an absolute reason not to use the medication.


Q: Are there specific genetic factors that affect how Asertin works?

A: Yes, specific genetic factors can affect how the body metabolizes this medication. The CYP2C19 enzyme, involved in its breakdown, can vary among individuals, which may affect drug levels.


Q: Is Asertin safe for older adults to take?

A: Official documents include guidelines for use in older adults, and the population typically requires careful dose consideration. Regulatory information indicates that older adults may be at a greater risk for conditions like Hyponatremia (low sodium levels). The decision regarding appropriate use is made by a healthcare professional based on individual status.


Q: What does the research say about Asertin's effectiveness?

A: The effectiveness of this medication is supported by Randomized Controlled Trials (RCTs) detailed in the official product information. These studies demonstrate measured changes in symptoms for conditions like Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and Panic Disorder compared to placebo.


Q: Are there specific food restrictions while on Asertin?

A: Regulatory documents state that Asertin tablets may be taken with or without food. However, if the oral solution is used, it must be diluted immediately before use with specific liquids only, such as water, ginger ale, lemon/lime soda, lemonade, or orange juice.


Q: Can Asertin be used by people with existing heart conditions?

A: Official warnings advise caution for patients with existing risk factors for QTc prolongation, which is a change in the heart's electrical rhythm. A healthcare professional must evaluate individual health history to determine appropriate use.


Q: What is serotonin syndrome, and is it a risk with Asertin?

A: Serotonin Syndrome is a potentially serious condition caused by excessive levels of serotonin, which can lead to symptoms like agitation, fever, and muscle stiffness. Regulatory warnings state that this medication carries a risk of this syndrome, particularly when combined with other serotonergic agents.


Q: Are there any long-term health concerns associated with Asertin use?

A: Regulatory warnings list several serious safety concerns that patients should be aware of, including the potential for Serotonin Syndrome and increased risk of bleeding. Official research also indicates that long-term study data remains limited for some of the conditions the medicine is used to treat.


Q: Is Asertin a mood stabilizer?

A: This medication is officially classified as a Selective Serotonin Reuptake Inhibitor (SSRI). While its general therapeutic purpose is described as mood and emotional stabilization, it is not classified as a traditional mood stabilizer.


Q: Do studies support the long-term use of Asertin?

A: Long-term use is supported by maintenance studies detailed in the official clinical trial information. These studies focus on the prevention of symptom relapse in patients who have already responded well to treatment for Major Depressive Disorder (MDD).


Q: Does Asertin have a 'black box' warning, and what does it mean?

A: Yes, the medication carries a Boxed Warning, which is the most serious warning required by the FDA. This warning highlights the increased risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults (up to age 24) during the initial months of treatment or following dose changes.

How should Asertin be stored and disposed of?

How to Store and Dispose of Asertin (Sertraline)

Official regulatory guidelines mandate specific conditions to ensure Asertin tablets remain stable and safe.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (CRT), typically 20 C to 25 C.
Protection Keep in the original, tight container and protect from light and moisture.
Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Disposal must follow established regulatory procedures. The preferred method for unused or expired tablets is via an official drug take-back program or authorized collection site. Sertraline is not on the FDA's flush list and should not be discarded in wastewater. If a take-back program is unavailable, follow the official procedure of mixing the medicine with an undesirable substance before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asertin found in:

A-Z Index: